International Journal of Drug Delivery Technology
Volume 16, Issue 4, 2026

Effectiveness of Intravesical Therapy Combined with Urethral Dilatation in the Management of Male Urethral Stricture: A Prospective Case Series

Dr. Harish Daga1*, Dr. Hemant D Toshikhane2, Dr. Ketul Patel3

1*Associate Professor, Department of Shalya Tantra, Parul Institute of Ayurveda, Parul University (Corresponding Author)

2Professor, Department of Shalya Tantra, Parul Institute of Ayurveda, Parul University

3Post Graduate Scholar, Department of Shalya Tantra, Parul Institute of Ayurveda, Parul University

Received: 15th Feb, 2026; Revised: 27th Feb 2026; Accepted: 20th Mar, 2026; Available Online: 5th Apr, 2026


ABSTRACT

Background and Objective: Male urethral stricture disease remains challenging to manage, as endoluminal treatments often provide rapid symptomatic relief but are associated with variable long-term patency. Integrative approaches combining conventional and traditional therapies may offer improved outcomes. This study aimed to evaluate the short-term functional and radiological outcomes of intravesical medicated oil instillation combined with serial urethral dilatation in men with urethral stricture disease.

Methods: A prospective case series was conducted in 10 men aged 27–66 years. Patients underwent daily transurethral intravesical medicated oil instillation for 15 days, along with scheduled urethral dilatation on days 5, 7, 9, and 11. Uroflowmetry parameters—maximum flow rate (Q-max), average flow rate (Q-avg), and post-void residual urine (PVR)—along with retrograde urethrogram (RGU), were assessed at baseline and post-treatment. Follow-up evaluations were performed at 30 and 60 days without self-dilatation.

Results: Mean Q max increased from 6.16 to 22.47 ml/s, and mean Q avg from 3.32 to 7.74 ml/s, while mean PVR decreased from 116.1 ml to 31.8 ml. Q max improved in all patients, Q avg in nine patients, and PVR in all patients. These improvements were sustained at 30- and 60-day follow-up, with no recurrence or requirement for additional intervention. RGU demonstrated complete resolution or significant improvement in urethral narrowing in the majority of patients, with no evidence of progression. No adverse events or urinary tract infections were reported.

Limitations: The study is limited by its small sample size, single-arm design, and short duration of follow-up.

Conclusions and Clinical Implications: This integrative treatment protocol appears to be feasible, safe, and associated with significant improvement in both functional and radiological outcomes in the short term. These findings support the need for larger, controlled studies with extended follow-up to validate long-term efficacy.

Keywords: Intravesical Instillation, Urethral dilatation, Urethral stricture, Uroflowmetry, Post-void residual urine, Lower Urinary Tract Symptoms

How to cite this article: Daga H, Toshikhane HD, Patel K. Effectiveness of Intravesical Therapy Combined with Urethral Dilatation in the Management of Male Urethral Stricture: A Prospective Case Series. Int J Drug Deliv Technol. 2026;16(4): 66. DOI: 10.25258/ijddt.16.4.9

Source of support: Nil.

Conflict of interest: None